A precision T-cell therapy stalls treatment-resistant cancers in clinical trial - Medical Xpress

A precision T-cell therapy stalls treatment-resistant cancers in clinical trial  Medical XpressBispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial  NatureMarengo Therapeutics Presents Phase 2 STARt-001 Results at ESMO 2026 Demonstrating Tissue-Agnostic Single-Agent Activity of Invikafusp Alfa in TMB-H Solid Tumors Mostly Unresponsive to Immune Checkpoint Blockade  AOL.comNovel cancer immunotherapy drug generates promising clinical trial results  Mass General BrighamESMO 2026: Marengo’s bispecific antibody shrinks 8 tumor types in Phase 2  BioSpace